We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Sea Bacteria May Offer New Way to Make Cancer Drugs

By Biotechdaily staff writers
Posted on 13 Nov 2006
Researchers have developed a novel method to make drugs for cancer and other diseases from bacteria found in sponges and other small ocean organisms. More...


In a study published November 5, 2006, in the online journal Nature Chemical Biology, researchers from the University of Utah (Salt Lake City, UT, USA) studied symbiotic bacteria that live only in sea squirts and other marine life. These bacteria are responsible for making a variety of chemicals, which accumulate in the tissues of sea squirts and may help to defend them against predators. Many of these compounds have anticancer properties, but harvesting them in quantities for large-scale testing and production has been impractical.

The new technique utilizes genetic pathways in the bacteria to generate the small chemical compounds and to manipulate them to devise new potential anti-cancer agents. The ability to make these chemicals in the laboratory opens numerous possibilities for developing drugs to combat cancer, HIV, and other disorders, according to Eric W. Schmidt, Ph.D., assistant professor of medicinal chemistry at the University of Utah College of Pharmacy and senior investigator on the study.

"This represents a new way of attacking the problem,” Dr. Schmidt said. "We're hoping we can use this to find a way to make natural molecules of compounds through single mutations in DNA.”

To synthesize natural compounds, researchers have conventionally produced them in the lab using labor-intensive techniques. More recently, researchers have started to use genes to produce small molecules within laboratory strains of bacteria. This genetic synthesis method is complex because it is still difficult to understand how changing genes can lead to changes in small drug molecules. "The promise of genes is that you can access the tremendous natural diversity of the world's organisms to find new natural compounds for human health,” Dr. Schmidt said. "You can also use genetic engineering to modify these compounds and invent new drugs to target human diseases.”

Sea squirts live with diverse bacteria that synthesize many small molecules. By studying the natural chemical and genetic diversity found in sea squirts and their symbionts, Dr. Schmidt and his colleagues from several institutions in the United States identified individual mutations responsible for changing from one compound to another. By mimicking this natural process, the investigators synthesized a totally new compound. This development may provide a way to genetically create of large chemical libraries for testing against human diseases. "This proves the concept works,” Dr. Schmidt said. "We can extract bacteria from animals, take DNA from the bacteria, and produce compounds.”

Now that the investigators have shown that compounds can be synthesized from DNA, they want to determine how to produce greater quantities of compounds for testing and drug development. Escherichia coli is a good producer of compounds, but production is not yet practical. For the study, Dr. Schmidt obtained sample bacteria from 46 ascidians in the tropical Pacific Ocean near New Guinea.



Related Links:
University of Utah

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.